Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism

Current Opinion in Lipidology

Volumn 15, Issue 3, 2004, Pages 255-260

  Albers, John J ^a   Cheung, Marian C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerotic lesions; Coronary artery disease; Lipoprotein metabolism; Mouse models; Phospholipid transfer protein; Reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER; CHYMASE; HIGH DENSITY LIPOPROTEIN; HYPOCHLOROUS ACID; LOW DENSITY LIPOPROTEIN; NEUTRAL PROTEINASE; PHOSPHOLIPID TRANSFER PROTEIN;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME RELEASE; EXPERIMENTAL MODEL; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPOPROTEIN METABOLISM; MACROPHAGE; MAST CELL; NONHUMAN; OBESITY; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL TRANSPORT; HUMANS; LIPID METABOLISM; LIPOPROTEINS; MACROPHAGES; MEMBRANE PROTEINS; MICE; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 2642554959     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200406000-00004     Document Type: Review

References (55)

1. Day JR, Albers JJ, Lofton-Day CE, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem 1994; 26912:9388-9391.
2. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993; 268:23098-23105.
3. Jauhiainen M, Metso J, Pahlman R, et al. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993; 268:4032-4036.
4. Jiang X, Francone OL, Bruce C, et al. Increased pre-beta high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996; 98:2373-2380.
5. van Haperen R, van Tol A, Vermeulen P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20:1082-1088.
6. Lie J, de Crom R, Jauhiainen M, et al. Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins. Biochem J 2001; 360:379-385.
7. Tall AR, Krumholz S, Olivecrona T, et al. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 1985; 26:842-851.
8. Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta 1999; 1439:65-76.
9. Jiang XC, Qin S, Qiao C, et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001; 7:847-852.
10. Lie J, de Crom R, van Gent T, et al. Elevation of plasma phospholipid transfer protein in transgenic mice increases very low density lipoprotein secretion. J Lipid Res 2002; 43:1875-1880.
11. Jiang XC, Bruce C, Mar J, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-914.
12. Yang XP, Yan D, Qiao C, et al. Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 2003; 23:1601-1607. This paper provides additional support to the notion that elevated PLTP is pro-atherogenic.
13. Post SM, De Crom R, Van Haperen R, et al. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. Arterioscler Thromb Vasc Biol 2003; 23:892-897.
14. Jonkers IJ, Smelt AH, Hattori H, et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 2003; 44:1462-1469.
15. Oka T, Kujiraoka T, Ito M, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000; 41:1651-1657.
16. Murdoch SJ, Carr MC, Kennedy H, et al. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res 2002; 43:1256-1263.
17. Kujiraoka T, Nanjee MN, Oka T, et al. Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb Vasc Biol 2003; 23:1653-1659.
18. Siggins S, Karkkainen M, Tenhunen J, et al. Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res 2004; 45:387-395.
19. Murdoch SJ, Carr MC, Hokanson JE, et al. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res 2000; 41:237-244.
20. Cheung MC, Knopp RH, Retzlaff B, et al. Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim Biophys Acta 2002; 1587:53-59.
21. Dullaart RP, Sluiter WJ, Dikkeschei LD, et al. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994; 24:188-194.
22. Kaser S, Sandhofer A, Foger B, et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001; 44:1111-1117.
23. Murdoch SJ, Kahn SE, Albers JJ, et al. PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J Lipid Res 2003; 44:1705-1712. This report suggests that elevated PLTP activity in obese individuals is a result of increased body fat, as reflected by abdominal subcutaneous fat, and is influenced by non-esterified fatty acids but is not directly related to insulin resistance.
24. Syeda F, Senault C, Delplanque B, et al. Postprandial variations in the cholesteryl ester transfer protein activity, phospholipid transfer protein activity and plasma cholesterol efflux capacity in normolipidemic men. Nutr Metab Cardiovasc Dis 2003; 13:28-36.
25. Tan KC, Shiu SW, Wong Y. Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 2003; 33:301-306.
26. Cheung MC, Sibley SD, Palmer JP, et al. Lipoprotein lipase and hepatic lipase: their relationship with HDL subspecies Lp(A-I) and Lp(A-I, A-II). J Lipid Res 2003; 44:1552-1558.
27. Schlitt A, Bickel C, Thumma P, et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23:1857-1862. This is the first study to suggest that plasma PLTP activity is an independent risk factor for coronary artery disease.
28. Soro A, Jauhiainen M, Ehnholm C, et al. Determinants of low HDL levels in familial combined hyperlipidemia. J Lipid Res 2003; 44:1536-1544.
29. Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, et al. Periodontitis decreases the antiatherogenic potency of high density lipoprotein (HDL). J Lipid Res 2004; 45:139-147.
30. Pussinen PJ, Metso J, Malle E, et al. The role of plasma phospholipid transfer protein (PLTP) in HDL remodeling in acute-phase patients. Biochim Biophys Acta 2001; 1533:153-163.
31. Barlage S, Frohlich D, Bottcher A, et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42:281-290.
32. Yatsuya H, Tamakoshi K, Hattori H, et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J 2003; 68:11-16.
33. Vuletic S, Jin L-W, Marcovina SM, et al. Widespread distribution of phospholipid transfer protein (PLTP) in human central nervous system: evidence for PLTP synthesis by glia and neurons and for increased levels in Alzheimer's disease. J Lipid Res 2003; 44:1113-1123. This is the first report to suggest that PLTP plays an important role in lipid and lipoprotein metabolism in the human central nervous system. The findings further suggest that PLTP could play a role in neurodegenerative disorders.
34. O'Brien K, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein (PLTP) in human coronary atherosclerosis. Circulation 2003; 108:270-274. PLTP immunostaining was widespread in human coronary atherosclerosis extracellularly and in association with foam cells of both macrophage and smooth muscle cell origin. Cholesterol loading of macrophages was also shown to upregulate PLTP expression in vitro.
35. Desrumaux CM, Mak PA, Boisvert WA, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003; 44:1453-1461. PLTP was present and was expressed in macrophage foam cells in human carotid atherosclerosis. Cholesterol loading upregulated PLTP expression in macrophages.
36. Laffitte BA, Joseph SB, Chen M, et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol 2003; 23:2182-2191. PLTP was highly expressed by macrophages within human atherosclerotic lesions. The PLTP gene was shown to be a liver X receptor target in both macrophages and liver cells.
37. Oram JF, Wolfbauer G, Vaugnan AM, et al. Phospholipid transfer protein interacts with and stabilizes ABCA1 and enhances efflux from cells. J Biol Chem 2003; 278:52379-52385.
38. 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol 1999; 19:1066-1074.
39. Lee M, Metso J, Jauhiainen M, et al. Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells. J Biol Chem 2003; 278:13539-13545. This report suggests that the release of chymase from mast cells in human atherosclerotic lesions may prevent the PLTP-dependent formation of pre-β HDL.
40. Tu AY, Deeb SS, Iwasaki L, et al. Organization of human phospholipid transfer protein gene. Biochem Biophys Res Commun 1995; 207:552-558.
41. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276:1861-1864.
42. Huuskonen J, Wohlfahrt G, Jauhiainen M, et al. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J Lipid Res 1999; 40:1123-1130.
43. Ponsin G, Qu SJ, Fan HZ, et al. Structural and functional determinants of human plasma phospholipid transfer protein activity as revealed by site-directed mutagenesis of charged amino acids. Biochemistry 2003; 42:4444-4451. These studies provide additional evidence to support the concept that the N-terminal pocket of PLTP is important for PLTP activity and the C-terminal pocket is important for HDL binding.
44. Siggins S, Jauhiainen M, Olkkonen VM, et al. PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res 2003; 44:1698-1704.
45. Karkkainen M, Oka T, Olkkonen VM, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 2002; 277:15413-15413.
46. Pussinen PJ, Metso J, Keva R, et al. Plasma phospholipid transfer protein-mediated reactions are impaired by hypochlorite-modification of high density lipoprotein. Int J Biochem Cell Biol 2003; 35:192-202. PLTP-mediated HDL conversion and preβ-HDL generation was impaired by the treatment of HDL with hypochlorite.
47. Urizar NL, Dowhan DH, Moore DD. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J Biol Chem 2000; 275:39313-39317.
48. Laffitte BA, Kast HR, Nguyen CM, et al. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000; 275:10638-10647.
49. Mak PA, Kast-Woelbern HR, Anisfeld AM, et al. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J Lipid Res 2002; 43:2037-2041.
50. Cao G, Beyer TP, Yang XP, et al. Phospholipid transfer protein is regulated by liver X receptors in vivo. J Biol Chem 2002; 277:39561-39565.
51. Korstanje R, Albers JJ, Wolfbauer G, et al. Quantitative trait locus mapping of genes that regulate phospholipid transfer activity in SM/J and NZB/B1NJ inbred mice. Arterioscler Thromb Vasc Biol 2004; 24:155-160.
52. Albers JJ, Pitman W, Wolfbauer G, et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strains. J Lipid Res 1999; 40:295-301.
53. Albers JJ, Wolfbauer G, Cheung MC, et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies. Biochim Biophys Acta 1995; 1258:27-34.
54. Masson D, Drouineaud V, Moiroux P, et al. Human seminal plasma displays significant phospholipid transfer activity due to the presence of active phospholipid transfer protein. Mol Hum Reprod 2003; 9:457-464.
55. Ravnik SE, Albers JJ, Muller CH. Stimulation of human sperm capacitation by purified lipid transfer protein. J Exp Zool 1995; 272:78-83.